Clinical trials: in Papua New Guinea
Yaws, Cutaneous Ulcer
Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)
The goal of this clinical trial is to test the non inferiority of linezolid compared with azithromycin as a treatment for yaws .
- Trial name
- Trep-AByaws (NCT05764876)
- Testing
- Linezolid Oral Tablet, Azithromycin Oral Tablet
- Where
- Papua New Guinea
- Volunteers
- 383 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Plasmodium Falciparum Malaria, Pregnancy Malaria
Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea
Malaria during pregnancy remains an important public health issue in endemic countries. Most cases of malaria in pregnant women are asymptomatic, and can contribute to adverse outcomes, such as maternal and neonatal anaemia as…
- Conditions
- Plasmodium Falciparum Malaria, Pregnancy Malaria, Diagnoses Disease
- Trial name
- NCT03462615
- Testing
- HS-RDT
- Where
- Papua New Guinea
- Volunteers
- 930 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Vivax Malaria, G6PD Deficiency
Short Course Primaquine for the Radical Cure of P. Vivax - Papua New Guinea
Significant gains have been made in reducing the overall burden of malaria worldwide, however these have been far greater for Plasmodium falciparum than P. vivax. P.
- Trial name
- SCOPE (NCT05874271)
- Testing
- Revised case management package
- Where
- 4 sites in Papua New Guinea
- Volunteers
- 794 people
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Cutaneous Ulcer Disease, Skin Sores
Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG - Second Trial
Small cutaneous ulcers are common in Papua New Guinea but are normally left untreated due to lack of easy access to basic medicines.
- Trial name
- UP2025 (NCT07264686)
- Testing
- Ficus septica exudate, Active Comparator: Savlon antiseptic cream (cetrimide with chlorhexidine digluconate)
- Where
- Papua New Guinea
- Volunteers
- 222 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Pharmacokinetics of Tafenoquine
Investigating the Pharmacokinetics of Tafenoquine in Healthy Papua New Guinean Children
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07052162
- Testing
- Single dose tafenoquine (10 mg/kg) given with water, Single dose tafenoquine (10 mg/kg) given with fat
- Where
- Papua New Guinea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Curtin University
Drug Pharmacokinetics in Healthy Volunteers
Postpartum 8-aminoquinoline Breast Milk Study
In Papua New Guinea, administration of primaquine (PQ) or tafenoquine (TQ) to breastfeeding mothers is contraindicated during the first six months postpartum, when infants are recommended to be exclusively breastfed, because of a…
- Trial name
- NCT07060404
- Testing
- Daily primaquine (0.5 mg/kg per day) for 14 days given with food food and water, Daily primaquine 1 mg/kg per day for 7 days given with food and water, Single-dose tafenoquine given with food and water to prevent gastrointestinal discomfort
- Where
- Papua New Guinea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Curtin University
Vivax Malaria, G6PD Deficiency
Primaquine for Vivax Malaria in G6PD Intermediate and Deficient Cases.
A non randomized observation study that is aiming to assess the safety and efficacy of high dose primaquine (1mg/kg per day over 7 days) among patients with intermediate (30-70%) G6PD activity and the safety and efficacy of…
- Trial name
- NCT07468513
- Testing
- Patients with G6PD enzyme activities between 30 and <70% of the AMM will be treated with schizontocidal treatment plus high dose primaquine 1mg/kg/day for 7 days, Patients with G6PD enzyme activities <30% of the AMM will be treated with schizontocidal treatment plus 8 weekly primaquine (0.75mg/kg dose).
- Where
- 4 sites in Brazil, Ethiopia and 1 more
- Volunteers
- 100 people
- Sponsor
- Menzies School of Health Research
Malaria
An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria
Current treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes, but this needs to be balanced against increased risk of side effects.
- Trial name
- PRIMUS (NCT07468526)
- Testing
- High dose ultra short Primaquine
- Where
- 5 sites in Ethiopia, Indonesia and 2 more
- Volunteers
- 1,019 people
- Sponsor
- Menzies School of Health Research
Uncomplicated Malaria
Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria
Plasmodium vivax is the most geographically widespread malaria species and the second largest contributor to symptomatic malaria worldwide.
- Trial name
- NCT07403643
- Testing
- Single dose tafenoquine (10 mg/kg), Dihydroartemisinin-piperaquine (DHA-PPQ), Artemether + Lumefantrine
- Where
- Papua New Guinea
- Volunteers
- 60 people
- Sponsor
- Curtin University
Vivax Malaria
A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria
The goal of this clinical trial is to assess the efficacy and safety or a revised weight band tafenoquine dose in vivax malaria patients.
- Trial name
- TADORE (NCT06148792)
- Testing
- Tafenoquine, Primaquine
- Where
- 4 sites in Brazil, Ethiopia and 2 more
- Volunteers
- 1,090 people
- Sponsor
- Menzies School of Health Research
Malaria, Malaria in Pregnancy
Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in Pregnancy
This trial tests the hypothesis that intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) plus dihydroartemisinin-piperaquine (DP) significantly reduces the risk of malaria infection (primary…
- Conditions
- Malaria, Malaria in Pregnancy, Pregnancy Related
- Trial name
- SAPOT (NCT05426434)
- Testing
- Dihydroartemisinin-Piperaquine (DP), Sulfadoxine pyrimethamine (SP)
- Where
- Papua New Guinea
- Volunteers
- 1,172 people, healthy volunteers welcome
- Sponsor
- Menzies School of Health Research
Emergencies
Emergency Department Triage in a Resource Constrained Setting: Application of the World Health Organization Triage Scale in Regional Papua New Guinea
Triage is an important component of emergency care (EC). It aims to sort patients based on the urgency of their condition such that the highest acuity patients are prioritised for assessment and treatment.
- Trial name
- NCT04098705
- Testing
- Introduction of the World Health Organization Triage Scale
- Where
- Papua New Guinea
- Sponsor
- Monash University
Cutaneous Ulcer Disease, Skin Sores
Ulcer Plants: Highly Accessible Plant Antiseptics for Use in Remote Areas of PNG
Small cutaneous ulcers are common in Papua New Guinea but are normally left untreated due to lack of easy access to basic medicines.
- Trial name
- UP2024 (NCT06690814)
- Testing
- Ficus septica exudate (antiseptic plant exudates), Pterocarpus indicus exudate, Curcuma longa aqueous extract
- Where
- Papua New Guinea
- Volunteers
- 370 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis
East New Britain Province Monitoring & Evaluation
While tremendous progress towards elimination of lymphatic filariasis (LF) has been made in the 20 years since the 1997 Fiftieth World Health Assembly, it is unlikely the goal of eliminating LF as a public health problem by 2020…
- Conditions
- Lymphatic Filariasis Elimination by Mass Drug Administration, Monitoring and Evaluation of Mass Drug Administration for Lymphatic Filariasis, Acceptability of Mass Drug Administration for Lymphatic Filariasis
- Trial name
- ENBP M&E (NCT04124250)
- Testing
- Observational
- Where
- Papua New Guinea
- Volunteers
- 12,930 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Newborn Vaccine Immunogenicity
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
Infection is the most common cause of death in early life, especially for newborns and can be reduced by immunization but insufficient knowledge of how vaccines protect the very young limits their optimal use.
- Trial name
- EPIC-HIPC (NCT03246230)
- Testing
- Hepatitis B vaccine (HBV), Bacillus Calmette-Guérin (BCG)
- Where
- 2 sites in Papua New Guinea, The Gambia
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Iodine Deficiency
Estimating Usual Iodine Intake From Spot Urinary Iodine Concentrations
The overall objective of this study is to develop a reliable method to obtain habitual iodine intakes from spot urinary iodine concentration (UIC) and to assess the prevalence of inadequate iodine intake in school-age children…
- Trial name
- ITURN (NCT03602404)
- Where
- 2 sites in Papua New Guinea, Russia
- Volunteers
- 1,592 people, healthy volunteers welcome
- Sponsor
- Swiss Federal Institute of Technology
Yaws
Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication
The current principle of yaws eradication (the Morges strategy) is based on single round mass drug administration (MDA) of azithromycin (AZI) called total community treatment (TCT) followed by targeted treatment of active cases…
- Trial name
- NCT03490123
- Testing
- R1-Total community treatment with azithromycin, R2-Total community treatment with azithromycin, R3-Total community treatment with azithromycin
- Where
- Papua New Guinea
- Volunteers
- 56,000 people, healthy volunteers welcome
- Sponsor
- Lihir Medical Centre
Lymphatic Filariasis
Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis
The DOLF Triple Drug Therapy for Lymphatic Filariasis study will determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB…
- Trial name
- NCT02899936
- Testing
- 3 drug dose - IDA, 2 drug dose - DA
- Where
- 4 sites in Haiti, India and 2 more
- Volunteers
- 23,789 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Lymphatic Filariases
Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis
This study will assess the impact of 2-drug (DA) or 3-drug (IDA) regimens on lymphatic filariasis infection parameters in communities.
- Trial name
- NCT03352206
- Testing
- 2 drug dose - DA, 3 drug dose - IDA
- Where
- 5 sites in Fiji, Haiti and 3 more
- Volunteers
- 20,092 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Yaws; Cutaneous, Cutaneous Ulcer
An Accessible Low-cost Plant Treatment for Cutaneous Ulcers
In a search for accessible treatment options, plant medicines used by different communities in Papua New Guinea have been tested to identify the sap of the tree, Ficus septica, as a promising antibacterial agent in vitro.
- Conditions
- Yaws; Cutaneous, Cutaneous Ulcer, Yaws
- Trial name
- NCT04453124
- Testing
- Topical antiseptic treatment
- Where
- 2 sites in Papua New Guinea
- Volunteers
- 150 people
- Sponsor
- Oriol Mitja